UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
British journal of dermatology (1951), ISSN 0007-0963, 05/2016, Volume 174, Issue 5, pp. 970 - 978
Life Sciences & Biomedicine | Dermatology | Science & Technology | Norgestrel - administration & dosage | Wound Closure Techniques | Etanercept - administration & dosage | Administration, Oral | Cyproterone Acetate - administration & dosage | Dermatologic Agents - administration & dosage | Humans | Hidradenitis Suppurativa - drug therapy | Treatment Outcome | Gentamicins - administration & dosage | Infliximab - administration & dosage | Adalimumab - administration & dosage | Clindamycin - administration & dosage | Quality of Life | Adult | Androgen Antagonists - administration & dosage | Ethinyl Estradiol - administration & dosage | Anti-Bacterial Agents - administration & dosage | Index Medicus | Systematic Review | Reviews
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10093, pp. 457 - 468
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Adalimumab - adverse effects | Arthritis, Rheumatoid - drug therapy | Pyrroles - administration & dosage | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Pyrroles - therapeutic use | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Piperidines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Treatment Outcome | Methotrexate - adverse effects | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Piperidines - therapeutic use | Pyrimidines - therapeutic use | Piperidines - adverse effects | Pyrimidines - adverse effects | Methotrexate - administration & dosage | Rheumatoid factor | Care and treatment | Analysis | Clinical trials | Arthritis | Pharmaceutical industry | Methotrexate | Rheumatology | Patients | Evidence-based medicine | Studies | Rheumatoid arthritis | Monoclonal antibodies | Rheumatism | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Safety | Drug therapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Annals of the rheumatic diseases, ISSN 0003-4967, 04/2014, Volume 73, Issue 4, pp. 654 - 661
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Triamcinolone - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Triamcinolone - adverse effects | Arthritis, Rheumatoid - drug therapy | Antirheumatic Agents - adverse effects | Adult | Female | Drug Therapy, Combination | Triamcinolone - therapeutic use | Arthritis, Rheumatoid - physiopathology | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Remission Induction | Methotrexate - adverse effects | Injections, Intra-Articular | Quality of Life | Methotrexate - administration & dosage | Aged | Adalimumab | Rheumatoid arthritis | Dosage and administration | Research | Methotrexate | Drug therapy | Triamcinolone | Studies | Pain | Clinical medicine | Quality of life | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 10006, pp. 1825 - 1834
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Azathioprine - administration & dosage | Azathioprine - therapeutic use | Immunosuppression - methods | Humans | Mercaptopurine - administration & dosage | Male | Treatment Outcome | Methotrexate - therapeutic use | Antimetabolites - therapeutic use | Infliximab - therapeutic use | Infliximab - administration & dosage | Antimetabolites - administration & dosage | Crohn Disease - therapy | Adalimumab - therapeutic use | Adalimumab - administration & dosage | Mercaptopurine - therapeutic use | Adult | Female | Methotrexate - administration & dosage | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Clinical trials | Gastrointestinal diseases | Immunotherapy | Algorithms | Surgery | Mortality | Gastroenterology | Drug therapy | Crohns disease | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Journal of investigative dermatology, ISSN 0022-202X, 11/2015, Volume 135, Issue 11, pp. 2632 - 2640
Life Sciences & Biomedicine | Dermatology | Science & Technology | Biological Therapy - methods | Prospective Studies | Biological Products - pharmacokinetics | Etanercept - administration & dosage | Humans | Middle Aged | Psoriasis - diagnosis | Male | Infliximab - administration & dosage | Infliximab - pharmacokinetics | Dose-Response Relationship, Drug | Societies, Medical | Etanercept - pharmacokinetics | Adult | Female | Registries | Ustekinumab - administration & dosage | Psoriasis - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Maximum Tolerated Dose | Adalimumab - administration & dosage | Ustekinumab - pharmacokinetics | Biological Products - administration & dosage | Cohort Studies | Index Medicus
Journal Article
Journal of rheumatology, ISSN 0315-162X, 03/2009, Volume 36, Issue 3, pp. 635 - 641
Pregnancy | Tumor necrosis factor antagonists | Safety | Life Sciences & Biomedicine | Rheumatology | Science & Technology | Biological and medical sciences | Diseases of the osteoarticular system | Medical sciences | United States - epidemiology | Prenatal Exposure Delayed Effects | Abnormalities, Drug-Induced - epidemiology | Humans | Antibodies, Monoclonal - adverse effects | Immunoglobulin G - adverse effects | Incidence | Antibodies, Monoclonal, Humanized | Etanercept | Infliximab | Receptors, Tumor Necrosis Factor | Antirheumatic Agents - adverse effects | Female | Registries | Adalimumab | Tumor Necrosis Factor-alpha - antagonists & inhibitors | United States Food and Drug Administration | Index Medicus
Journal Article
Drug metabolism and disposition, ISSN 0090-9556, 07/2016, Volume 44, Issue 7, pp. 924 - 933
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Age Factors | Esomeprazole - administration & dosage | Humans | Seizures - drug therapy | Child, Preschool | Anticonvulsants - administration & dosage | Infant | Adolescent Development | Drug Approval | Anti-HIV Agents - administration & dosage | Dose-Response Relationship, Drug | Drug Dosage Calculations | Proton Pump Inhibitors - administration & dosage | Vigabatrin - administration & dosage | Adalimumab - pharmacokinetics | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Child Development | Gastroesophageal Reflux - drug therapy | Pharmaceutical Preparations - administration & dosage | Child | Infant, Newborn | Anticonvulsants - pharmacokinetics | Esomeprazole - pharmacokinetics | Drug Labeling | Pharmaceutical Preparations - metabolism | Adalimumab - administration & dosage | Proton Pump Inhibitors - pharmacokinetics | Models, Biological | Vigabatrin - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Crohn Disease - drug therapy | Adolescent | HIV Infections - drug therapy | Pharmacokinetics | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 16, pp. 1537 - 1550
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Disability Evaluation | Piperidines - administration & dosage | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Adalimumab - adverse effects | Dose-Response Relationship, Drug | Janus Kinases - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Adalimumab - therapeutic use | Pyrroles - administration & dosage | Arthritis, Psoriatic - drug therapy | Piperidines - adverse effects | Pyrimidines - adverse effects | Antirheumatic Agents - adverse effects | Pyrroles - adverse effects | Adult | Female | Drug Therapy, Combination | Antirheumatic Agents - therapeutic use | Care and treatment | Antirheumatic agents | Research | Management | Patients | Psoriatic arthritis | Herpes zoster | Inhibitor drugs | Psoriasis | Cytokines | Rheumatology | Arthritis | Joint diseases | Monoclonal antibodies | TNF inhibitors | Janus kinase | Tumor necrosis factor-TNF | Drug therapy | Cancer | Index Medicus | Abridged Index Medicus
Journal Article